Is the angiotensin receptor blocker cancer risk overstated?

By  

Reactions Weekly, Vol. 1, Iss. 1351, 2011-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Erratum: Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone

By  

Cancer, Vol. 121, Iss. 17, 2015-09 ,pp. : 3048-3048

Blackwell Publishing

Access to resources Recommend Favorite

Efficacy and Safety of Angiotensin II Type 1 Receptor Blocker/Calcium Channel Blocker Combination Therapy for Hypertension: Focus on a Single-pill Fixed-dose Combination of Valsartan and Amlodipine

By Miura S   Saku K  

The Journal of International Medical Research, Vol. 40, Iss. 1, 2012-01 ,pp. : 1-9

Field House Publishing

Access to resources Recommend Favorite

Additive Effect of TAK-491, a New Angiotensin Receptor Blocker, and Pioglitazone, in Reducing Myocardial Infarct Size

By Ye Yumei   Keyes Kyle   Zhang Chong   Perez-Polo Jose   Lin Yu   Birnbaum Yochai  

Cardiovascular Drugs and Therapy, Vol. 24, Iss. 2, 2010-04 ,pp. : 107-120

Springer Publishing Company

Access to resources Recommend Favorite

Valsartan: a novel angiotensin Type 1 receptor antagonist

By Thürmann P.A.  

Expert Opinion on Pharmacotherapy, Vol. 1, Iss. 2, 2000-01 ,pp. : 337-350

Informa Healthcare

Access to resources Recommend Favorite